Abstracts tagged "Disease Activity"

Abstract Number: 0800 • ACR Convergence 2021
Digital Spatial Profiling Reveals Distinct Synovial Tissue Transcriptomic Signature of Sustained Disease Remission in Rheumatoid Arthritis Patients at Risk of Disease Flare After Treatment Tapering or Discontinuation
Stefano Alivernini¹, Simone Perniola², Marco Gessi³, Maria Rita Gigante⁴, Clara Di Mario⁵, Luca Petricca⁴, Dario Bruno⁵, Laura Bui¹, Annamaria Paglionico¹, Valentina Varriano¹, Maria Antonietta D'Agostino⁶, Barbara Tolusso¹ and Elisa Gremese⁷, ¹Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Fondazione Policlinico Universitario A. Gemelli IRCCS - University of Verona, Santeramo in Colle, Italy, ³Fondazione PoliclinicoUniversitario A. Gemelli IRCCS, Rome, Italy, ⁴Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy, ⁶Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, ⁷Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
Background/Purpose: Sustained disease remission is the treatment goal for Rheumatoid Arthritis (RA) leading patients to be eligible to treatment tapering or discontinuation. However, disease flare…
Abstract Number: 0978 • ACR Convergence 2021
Immunological and Clinical Features of Untreated Juvenile Dermatomyositis Patients with Elevated Neopterin
Amer Khojah¹, Gabrielle Morgan² and Lauren Pachman³, ¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ²Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ³Northwestern's Feinberg School of Medicine. Ann and Robert H. Lurie Children's Hospital of Chicago; Stanley Manne Children's Research Institute of Chicago, Lake Forest, IL
Background/Purpose: Neopterin is a metabolic product of guanosine triphosphate, which is produced by macrophages upon stimulation with interferon-gamma from activated T helper cells. Despite the…
Abstract Number: 1253 • ACR Convergence 2021
Acupuncture in Rheumatoid Arthritis Activity
Diana Seixas¹, Fátima Farinha², Marcos Pacheco da Fonte³, Manuel Laranjeira¹ and Marília Rua⁴, ¹ICBAS, Porto, Portugal, ²CHUP-HSA, Porto, Portugal, ³CHEDV, Santa Maria da Feira, Portugal, ⁴University Aveiro, Aveiro, Portugal
Background/Purpose: High activity rates of Rheumatoid Arthritis (RA) lead to an increased risk of mortality. RA patients have a high incidence of comorbidities, associated with…
Abstract Number: 1498 • ACR Convergence 2021
Platelet Secreted LGALS3BP Induces a Pro-inflammatory Phenotype in Systemic Lupus Erythematosus
Hanane EL Bannoudi¹, MacIntosh Cornwell², Elliot Luttrell-Williams², Alexis Engel³, Christina Rolling¹, Peter Izmirly⁴, H. Michael Belmont⁵, Kelly Ruggles², Robert Clancy⁶, Jill Buyon⁵ and Jeffrey Berger², ¹NYU Langone Health, New York, NY, ²New York University, New York, NY, ³NYU Langone Health, New Yok, NY, ⁴New York University School of Medicine, New York, NY, ⁵NYU School of Medicine, New York, NY, ⁶NYU Grossman School of Medicine, New York, NY
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex chronic heterogeneous autoimmune disease, which increases the risk of atherothrombosis. In addition to their well described role…
Abstract Number: 1799 • ACR Convergence 2021
Gender Based Differences in Clinical and Sonographic Assessment Among Patients with Psoriatic Arthritis
Victoria Furer¹, Jonathan Wollman², David levartovsky³, Valerie Aloush³, Sara Borok Lev-Ran⁴, Daphna Paran⁵, Ori Elkayam³ and Ari Polachek⁶, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Herzliya, Israel, ³Tel Aviv Medical Center, Tel Aviv, Israel, ⁴Sourasky Medical Center, Tel AViv, Israel, ⁵Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ⁶Sourasky Medical Center, Petah-Tikva, Israel
Background/Purpose: Psoriatic arthritis (PsA) can affect differently women and men. Ultrasound (US) is an important tool in the evaluation of disease activity of PsA. To…
Abstract Number: 0255 • ACR Convergence 2021
Identification of Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Fenglong Xie¹, Timothy Beukelman¹, Jeffrey Curtis² and , for the CARRA Registry Investigators³, ¹University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ³CARRA, Durham, NC
Background/Purpose: Recent treat to target recommendations for the treatment of juvenile idiopathic arthritis (JIA) recommend frequent evaluation and treatment intensification until the disease activity target…
Abstract Number: 0604 • ACR Convergence 2021
Disparities in Burden of Disease in Patients with RA Across Racial and Ethnic Groups
Jacqueline O’Brien¹, Sang Hee Park², Taylor Blachley¹, Maya Marchese¹, Nicole Middaugh¹, Xue Han², Keith Wittstock² and Leslie Harrold¹, ¹CorEvitas, LLC, Waltham, MA, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Prior research has shown that differences exist in disease activity and clinical outcomes for RA across racial and ethnic groups in the US.1 This…
Abstract Number: 0813 • ACR Convergence 2021
Improvement in Clinical Disease Activity and Patient-Reported Outcomes After 6 Months of Treatment with Abatacept, Stratified by Line of Therapy, in Patients with RA: Results from a Large, US, National Observational Study
Leslie Harrold¹, Keith Wittstock², Sheila Kelly², Sang Hee Park², Xue Han², Ying Shan¹, Carla Roberts-Toler¹, Nicole Middaugh¹ and Vadim Khaychuk², ¹CorEvitas, LLC, Waltham, MA, ²Bristol Myers Squibb, Princeton, NJ
Background/Purpose: RA is more responsive to treatment in the early stages of disease, and early treatment may lead to better long-term outcomes.1,2 Data on the…
Abstract Number: 0985 • ACR Convergence 2021
Sjӧgren’s Symptom Burden Drives Immunomodulatory Therapies but Correlates Poorly with Disease Severity Markers
Sara McCoy¹, Miguel Woodham¹, Ian Saldanha², Esen Akpek³, VATINEE BUNYA⁴ and Alan Baer⁵, ¹University of Wisconsin, Madison, WI, ²Brown University School of Public Health, Providence, RI, ³Wilmer Eye Institute, JHU, Baltimore, MD, ⁴University of Pennsylvania, Penn Valley, PA, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sjӧgren’s syndrome (SS) patients have lower quality of life driven by symptoms of pain, depression and fatigue. These symptoms often do not respond to…
Abstract Number: 1274 • ACR Convergence 2021
Severe Flares Are Associated with a Poorer Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE) Patients
Manuel Ugarte-Gil¹, Rocio Gamboa-Cardenas², Cristina Reategui-Sokolova³, Victor Pimentel-Quiroz¹, Mariela Medina⁴, Claudia Elera-Fitzcarrald², Francisco Zevallos⁴, Cesar Pastor-Asurza⁵, Federico Zazzetti⁶, Chetan Karyekar⁷, Risto Perich-Campos⁵ and Graciela Alarcn⁸, ¹Hospital Guillermo Almenara Irigoyen, Essalud/Universidad Científica del Sur, Lima, Peru, ²Universidad Cientifica del Sur/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ³Hospital Guillermo Almenara Irigoyen, Lima, Peru, ⁴Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁵Universidad Nacional Mayor de San Marcos/Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, ⁷Janssen R&D, Spring House, PA, ⁸University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Flares in SLE patients, regardless of their severity, have been associated with damage accrual. However, their impact on HRQoL has not been fully evaluated.…
Abstract Number: 1500 • ACR Convergence 2021
Expression of Neuropilin-1 Is Significantly Increased in Dendritic Cells and CD4 + T Cells and It Correlates Disease Activity in the Patients with Systemic Lupus Erythematosus
Yunjung Choi¹, Eun-gyeong Lee¹, Yu-Mi Lee², Myeung-Su Lee³, Chang-Hoon Lee³, Chong Hyuk Chung³ and Wan-Hee yoo¹, ¹Research Institute of Clinical Medicine of Jeonbuk national university-Biomedical Research Institute of Jeonbuk national university hospital, Jeonju, Republic of Korea, ²Jeonbuk National University Hospital, Jeonju, Republic of Korea, ³Wonkwang University Hospital, Iksan, Republic of Korea
Background/Purpose: Neuropilin-1 (NRP-1) is a transmembrane glycoprotein that acts as a receptor of class III/IV semaphorins which role in the pathogenesis of autoimmune diseases. The…
Abstract Number: 1809 • ACR Convergence 2021
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
Philip Mease¹, Ana-Maria Orbai², Oliver FitzGerald³, Mohamed Bedaiwi⁴, Dona L Fleishaker⁵, Rajiv Mundayat⁶, Pamela Young⁷ and Philip S Helliwell⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Division of Rheumatology, College of Medicine, King Saud University Medical City, Riyadh, Saudi Arabia, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Enthesitis (inflammation where the tendon, ligament, or joint capsule insert into the bone) has been associated with higher disease activity and reduced quality of…
Abstract Number: 0272 • ACR Convergence 2021
RA Disease Activity Is an Independent Predictor of Left Ventricular Mass Changes in an RA Cohort Without Cardiovascular Disease
Elizabeth Park¹, Kazato Ito¹, Christopher Depender¹, Jon Giles¹ and Joan Bathon², ¹Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, ²Columbia University, New York, NY
Background/Purpose: Rheumatoid arthritis (RA) patients have 50% increased risk of heart failure (HF) vs non-RA patients with a distinct phenotype, preserved ejection fraction on transthoracic…
Abstract Number: 0605 • ACR Convergence 2021
Impact of Area of Residence on Perceptions of Health and Disease Activity in Ethnic Minorities with Rheumatoid Arthritis in an Urban Setting
Mohamed Jalloh¹, Sharon Dowell², Richard Ogunti¹ and Gail Kerr³, ¹Howard University Internal Medicine Residency, Washington, DC, ²Howard University College of Medicine, Washington, DC, ³Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Health care disparities in hypertension and other chronic disease are well established. Ethnic minority residents of Washington DC, particularly Wards 7 and 8, have…
Abstract Number: 0818 • ACR Convergence 2021
Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
Nancy Guo¹, Xiuying Li², Mohammad Movahedi³, Angela Cesta⁴ and Claire Bombardier⁵, ¹Kingston General Hospital, Kingston, ON, Canada, ²OBRI at University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Prior studies have shown that in the real-world setting, rheumatoid arthritis (RA) patients have lower disease activity than those studied in clinical trials. However,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].